It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication
As the result, D-Allulose is a valuable blood glucose management tool for healthy humans and diabetes patients
Without such a solution, powdered medications cannot be given to patients effectively
Simpson T, Kure C, Stough C
Likewise, the results of large clinical trials employing cardiovascular surrogate markers as their secondary outcomes also imply the potential beneficial effects of GLP-1 RAs in the cardiovascular system in human subjects
Frequently asked questions HELPFUL LINKS Get in touch [email protected] Important: For media inquiries or interview requests only